Compare BridgeBio Pharma Inc (BBIO) vs Huntington Ingalls Industries Inc (HII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Huntington Ingalls Industries Inc — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Huntington Ingalls Industries Inc trades at $327.5 (market cap $12.92B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Huntington Ingalls Industries Inc pays a 1.68% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | HII | |
|---|---|---|
Market Cap | $16.36B | $12.92B |
Sector | Health | Technology |
52-Week High | $90.17 | $453.73 |
52-Week Low | $47.29 | $265.40 |
Enterprise Value | $18.14B | $15.84B |
Dividend Yield | — | 1.68% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Huntington Ingalls Industries Inc
Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.
Read more on HII →
